securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans in Canada; and (vii) InterMune's ability to obtain or maintain patent or other proprietary intellectual property protections. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K, Form 10-Q and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at
www.intermune.com.Esbriet
® is a registered trademark of InterMune, Inc.
Financial tables follow:InterMune, Inc.PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited, in thousands, except per share amounts)Three Months EndedNine Months EndedSeptember 30,September 30,2012201120122011Revenue, net Esbriet
$
7,534$
118
$
17,952$
118 Collaboration revenue-0-2,629Total revenue, net7,53411817,9522,747Costs and expenses: Cost of goods sold2,0173856,200385 Research and development26,17517,04574,55353,967 Selling, general and administrative23,75423,65275,68062,661Total costs and expenses51,94641,082156,433117,013Loss from operations(44,412)(40,964)(138,481)(114,266)Interest income148131452390Interest expense(2,031)(1,281)(6,473)(4,154)Other income (expense)975(227)(149)(322)Loss from operations before income taxes(45,320)(42,341)(144,651)(118,352)Income tax expense192-326-Loss from continuing operations (45,512)(42,341)(144,977)(118,352)Discontinued operations:Income from discontinued operations1324,0972,1258,111Gain on sale of discontinued operations--51,335-Income from discontinued operations1324,09753,4608,111Net loss
$
(45,380)$
(38,244)
$
(91,517)$
(110,241)Basic and diluted net income (loss) per common share:Continu
'/>"/>
SOURCE InterMune, Inc. Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 Related biology technology :1.
InterMune To Release Third Quarter Financial Results On November 72.
InterMune To Present At JMP Securities Healthcare Conference3.
InterMune to Release Fourth Quarter and Full Year Financial Results on February 94.
InterMune to Present at J. P. Morgan Healthcare Conference5.
InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 56.
PharmAthene Reports Third Quarter 2012 Financial Results7.
VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting8.
Patient Safety Technologies Reports Third Quarter 2012 Results9.
PDI Reports 2012 Third Quarter Financial Results10.
Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting11.
Neurocrine Biosciences Reports Third Quarter 2012 Results